TP53 and pachyonychia congenita: Despite genetic and epigenetic research identifying key alterations driving the progression of PC, such as the mutations in Kras, p53, and SMAD4, none of these targets have resulted in effective therapies, making PC is still one of the most challenging cancers to treat (4).